Murewanhema Grant, Musuka Godfrey, Denhere Knowledge, Chingombe Innocent, Mapingure Munyaradzi Paul, Dzinamarira Tafadzwa
Unit of Obstetrics and Gynaecology, Department of Primary Health Care Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare P.O. Box MP167, Zimbabwe.
ICAP, Columbia University, Harare P.O. Box MP167, Zimbabwe.
Vaccines (Basel). 2022 Feb 9;10(2):262. doi: 10.3390/vaccines10020262.
The ongoing COVID-19 pandemic brought unprecedented challenges for the population. The advent of national COVID-19 vaccination programmes was therefore welcome as a key control strategy for the COVID-19 pandemic, as evidence has shown that vaccination is the best strategy to reduce the adverse individual and population level adverse outcomes associated with infectious diseases such as COVID-19. Zimbabwe rolled out its vaccination programme in February 2021 with an ambitious target to vaccinate at least 60% of its eligible population by December 2021. However, by that time, the country was still to reach that target. To move the vaccination programme towards achieving this target, it is crucial to understand the strengths, weaknesses, opportunities and threats to the programme. We, therefore, with this narrative review, discuss some of the strengths, weaknesses, opportunities and threats to the programme since its rollout in February 2021. Though the programme has several strengths and opportunities to leverage on, we argue that among other challenges, the emergence of new variants of concern poses one of the biggest threats to local, regional and international vaccination programmes and requires concerted multistakeholder efforts to deal with. Additionally, addressing vaccine hesitancy remains as important as availing the vaccines to the population, to obtain the most benefits out of the programme.
持续的新冠疫情给民众带来了前所未有的挑战。因此,国家新冠疫苗接种计划的出台受到欢迎,它是新冠疫情的一项关键防控策略,因为有证据表明,接种疫苗是减少与新冠等传染病相关的个人和群体不良后果的最佳策略。津巴布韦于2021年2月推出了其疫苗接种计划,目标宏伟,要在2021年12月前为至少60%的符合条件人口接种疫苗。然而,到那时该国仍未实现这一目标。为推动疫苗接种计划实现这一目标,了解该计划的优势、劣势、机遇和威胁至关重要。因此,我们通过这篇叙述性综述,讨论自2021年2月该计划推出以来的一些优势、劣势、机遇和威胁。尽管该计划有诸多优势和机遇可加以利用,但我们认为,在其他挑战中,新出现的值得关注的变异毒株对本地、区域和国际疫苗接种计划构成了最大威胁之一,需要多方利益相关者共同努力应对。此外,解决疫苗犹豫问题与向民众提供疫苗同样重要,以便从该计划中获得最大益处。